Selected research
Industry Research
FIC Dual-target Drugs Industry Research Report 2026
Market perspective
The global FIC Dual-target Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for FIC Dual-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for FIC Dual-target Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for FIC Dual-target Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of FIC Dual-target Drugs include Agios, BMS, Boehringer Ingelheim, Dermavant Sciences, Genentech, Gilead, Immunocore, ImmunoGen and Mallinckrodt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global FIC Dual-target Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
FIC Dual-target Drugs Market by Company
Agios
BMS
Boehringer Ingelheim
Dermavant Sciences
Genentech
Gilead
Immunocore
ImmunoGen
Mallinckrodt
Marinus
Phathom
Polarean lmaging
Pfizer
Eli Lilly
Roche
Merck
Novartis
Johnson & Johnson
Sanofi
FIC Dual-target Drugs Segment by Type
Polθ/PARP Targets
GPX4/CDK Targets
EZH2/HSP90 Targets
Others
FIC Dual-target Drugs Segment by Application
Hospital
Clinic
Other
FIC Dual-target Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Dual-target Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of FIC Dual-target Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Dual-target Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of FIC Dual-target Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of FIC Dual-target Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of FIC Dual-target Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polθ/PARP Targets
- GPX4/CDK Targets
- EZH2/HSP90 Targets
- Others
Applications
- Hospital
- Clinic
- Other
Companies covered
- Agios
- BMS
- Boehringer Ingelheim
- Dermavant Sciences
- Genentech
- Gilead
- Immunocore
- ImmunoGen
- Mallinckrodt
- Marinus
- Phathom
- Polarean lmaging
- Pfizer
- Eli Lilly
- Roche
- Merck
- Novartis
- Johnson & Johnson
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global FIC Dual-target Drugs Market Size (2021-2032)
- 2.2.2 Global FIC Dual-target Drugs Sales (2021-2032)
- 2.2.3 Global FIC Dual-target Drugs Market Average Price (2021-2032)
- 2.3 FIC Dual-target Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Polθ/PARP Targets
- 2.3.3 GPX4/CDK Targets
- 2.3.4 EZH2/HSP90 Targets
- 2.3.5 Others
- 2.4 FIC Dual-target Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global FIC Dual-target Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global FIC Dual-target Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global FIC Dual-target Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global FIC Dual-target Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global FIC Dual-target Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of FIC Dual-target Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of FIC Dual-target Drugs, Product Type & Application
- 3.8 Global Manufacturers of FIC Dual-target Drugs, Established Date
- 3.9 Global FIC Dual-target Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Agios
- 4.1.1 Agios Company Information
- 4.1.2 Agios Business Overview
- 4.1.3 Agios FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Agios FIC Dual-target Drugs Product Portfolio
- 4.1.5 Agios Recent Developments
- 4.2 BMS
- 4.2.1 BMS Company Information
- 4.2.2 BMS Business Overview
- 4.2.3 BMS FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 BMS FIC Dual-target Drugs Product Portfolio
- 4.2.5 BMS Recent Developments
- 4.3 Boehringer Ingelheim
- 4.3.1 Boehringer Ingelheim Company Information
- 4.3.2 Boehringer Ingelheim Business Overview
- 4.3.3 Boehringer Ingelheim FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Boehringer Ingelheim FIC Dual-target Drugs Product Portfolio
- 4.3.5 Boehringer Ingelheim Recent Developments
- 4.4 Dermavant Sciences
- 4.4.1 Dermavant Sciences Company Information
- 4.4.2 Dermavant Sciences Business Overview
- 4.4.3 Dermavant Sciences FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dermavant Sciences FIC Dual-target Drugs Product Portfolio
- 4.4.5 Dermavant Sciences Recent Developments
- 4.5 Genentech
- 4.5.1 Genentech Company Information
- 4.5.2 Genentech Business Overview
- 4.5.3 Genentech FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Genentech FIC Dual-target Drugs Product Portfolio
- 4.5.5 Genentech Recent Developments
- 4.6 Gilead
- 4.6.1 Gilead Company Information
- 4.6.2 Gilead Business Overview
- 4.6.3 Gilead FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Gilead FIC Dual-target Drugs Product Portfolio
- 4.6.5 Gilead Recent Developments
- 4.7 Immunocore
- 4.7.1 Immunocore Company Information
- 4.7.2 Immunocore Business Overview
- 4.7.3 Immunocore FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Immunocore FIC Dual-target Drugs Product Portfolio
- 4.7.5 Immunocore Recent Developments
- 4.8 ImmunoGen
- 4.8.1 ImmunoGen Company Information
- 4.8.2 ImmunoGen Business Overview
- 4.8.3 ImmunoGen FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 ImmunoGen FIC Dual-target Drugs Product Portfolio
- 4.8.5 ImmunoGen Recent Developments
- 4.9 Mallinckrodt
- 4.9.1 Mallinckrodt Company Information
- 4.9.2 Mallinckrodt Business Overview
- 4.9.3 Mallinckrodt FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mallinckrodt FIC Dual-target Drugs Product Portfolio
- 4.9.5 Mallinckrodt Recent Developments
- 4.10 Marinus
- 4.10.1 Marinus Company Information
- 4.10.2 Marinus Business Overview
- 4.10.3 Marinus FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Marinus FIC Dual-target Drugs Product Portfolio
- 4.10.5 Marinus Recent Developments
- 4.11 Phathom
- 4.11.1 Phathom Company Information
- 4.11.2 Phathom Business Overview
- 4.11.3 Phathom FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Phathom FIC Dual-target Drugs Product Portfolio
- 4.11.5 Phathom Recent Developments
- 4.12 Polarean lmaging
- 4.12.1 Polarean lmaging Company Information
- 4.12.2 Polarean lmaging Business Overview
- 4.12.3 Polarean lmaging FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Polarean lmaging FIC Dual-target Drugs Product Portfolio
- 4.12.5 Polarean lmaging Recent Developments
- 4.13 Pfizer
- 4.13.1 Pfizer Company Information
- 4.13.2 Pfizer Business Overview
- 4.13.3 Pfizer FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Pfizer FIC Dual-target Drugs Product Portfolio
- 4.13.5 Pfizer Recent Developments
- 4.14 Eli Lilly
- 4.14.1 Eli Lilly Company Information
- 4.14.2 Eli Lilly Business Overview
- 4.14.3 Eli Lilly FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Eli Lilly FIC Dual-target Drugs Product Portfolio
- 4.14.5 Eli Lilly Recent Developments
- 4.15 Roche
- 4.15.1 Roche Company Information
- 4.15.2 Roche Business Overview
- 4.15.3 Roche FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Roche FIC Dual-target Drugs Product Portfolio
- 4.15.5 Roche Recent Developments
- 4.16 Merck
- 4.16.1 Merck Company Information
- 4.16.2 Merck Business Overview
- 4.16.3 Merck FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Merck FIC Dual-target Drugs Product Portfolio
- 4.16.5 Merck Recent Developments
- 4.17 Novartis
- 4.17.1 Novartis Company Information
- 4.17.2 Novartis Business Overview
- 4.17.3 Novartis FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Novartis FIC Dual-target Drugs Product Portfolio
- 4.17.5 Novartis Recent Developments
- 4.18 Johnson & Johnson
- 4.18.1 Johnson & Johnson Company Information
- 4.18.2 Johnson & Johnson Business Overview
- 4.18.3 Johnson & Johnson FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Johnson & Johnson FIC Dual-target Drugs Product Portfolio
- 4.18.5 Johnson & Johnson Recent Developments
- 4.19 Sanofi
- 4.19.1 Sanofi Company Information
- 4.19.2 Sanofi Business Overview
- 4.19.3 Sanofi FIC Dual-target Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Sanofi FIC Dual-target Drugs Product Portfolio
- 4.19.5 Sanofi Recent Developments
5 Global FIC Dual-target Drugs Market Scenario by Region
- 5.1 Global FIC Dual-target Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global FIC Dual-target Drugs Sales by Region: 2021-2032
- 5.2.1 Global FIC Dual-target Drugs Sales by Region: 2021-2026
- 5.2.2 Global FIC Dual-target Drugs Sales by Region: 2027-2032
- 5.3 Global FIC Dual-target Drugs Revenue by Region: 2021-2032
- 5.3.1 Global FIC Dual-target Drugs Revenue by Region: 2021-2026
- 5.3.2 Global FIC Dual-target Drugs Revenue by Region: 2027-2032
- 5.4 North America FIC Dual-target Drugs Market Facts & Figures by Country
- 5.4.1 North America FIC Dual-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America FIC Dual-target Drugs Sales by Country (2021-2032)
- 5.4.3 North America FIC Dual-target Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe FIC Dual-target Drugs Market Facts & Figures by Country
- 5.5.1 Europe FIC Dual-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe FIC Dual-target Drugs Sales by Country (2021-2032)
- 5.5.3 Europe FIC Dual-target Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific FIC Dual-target Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific FIC Dual-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific FIC Dual-target Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific FIC Dual-target Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America FIC Dual-target Drugs Market Facts & Figures by Country
- 5.7.1 South America FIC Dual-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America FIC Dual-target Drugs Sales by Country (2021-2032)
- 5.7.3 South America FIC Dual-target Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa FIC Dual-target Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa FIC Dual-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa FIC Dual-target Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa FIC Dual-target Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global FIC Dual-target Drugs Sales by Type (2021-2032)
- 6.1.1 Global FIC Dual-target Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global FIC Dual-target Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global FIC Dual-target Drugs Revenue by Type (2021-2032)
- 6.2.1 Global FIC Dual-target Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global FIC Dual-target Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global FIC Dual-target Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global FIC Dual-target Drugs Sales by Application (2021-2032)
- 7.1.1 Global FIC Dual-target Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global FIC Dual-target Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global FIC Dual-target Drugs Revenue by Application (2021-2032)
- 7.2.1 Global FIC Dual-target Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global FIC Dual-target Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global FIC Dual-target Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 FIC Dual-target Drugs Value Chain Analysis
- 8.1.1 FIC Dual-target Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 FIC Dual-target Drugs Production Mode & Process
- 8.2 FIC Dual-target Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 FIC Dual-target Drugs Distributors
- 8.2.3 FIC Dual-target Drugs Customers
9 Global FIC Dual-target Drugs Analyzing Market Dynamics
- 9.1 FIC Dual-target Drugs Industry Trends
- 9.2 FIC Dual-target Drugs Industry Drivers
- 9.3 FIC Dual-target Drugs Industry Opportunities and Challenges
- 9.4 FIC Dual-target Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst